ClinicalTrials.gg
CompletedNCT02974439Updated Oct 13, 2017

Bioequivalence Study of Amlodipine and Norvasc Under Fasting and FED Conditions in Chinese Healthy Volunteers

A Phase 1 interventional study of LANDI-Amlodipine Besylate Tablet 5mg and Norvasc Tablets 5mg in Bioequivalence, sponsored by Shanghai Haini Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-13.

Sponsored by Shanghai Haini Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study evaluates the pharmacokinetics and bioequivalence of Amlodipine Besylate Tablets 5 mg versus Norvasc 5 mg tablets administered as 5 mg tablet in healthy volunteers with a washout period of 14 days

Read the detailed description

The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study with a washout period of 14 days. During each session, the subjects will be administered a single dose of 5mg amlodipine (one LANDI-Amlodipine Tablet 5mg or one Norvasc Tablet 5mg) under fasting and FED conditions.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

This is the only study on the registry with Shanghai Haini Pharmaceutical Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers of 18-40 years old, male or female.
  2. (BMI) ranges from 19.0 to 25.0 kg/m2, body weight ≥ 50 kg for male and 45 kg for female.
  3. No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system, neural abnormities or metabolic abnormalities; No preparation allergies, serious infection or injury, etc.
  4. Medically healthy subjects with clinically normal laboratory profiles and ECGs.
  5. Subjects must agree to take effective methods to prevent pregnancy from the start of screening until 3 months of last dose administration
  6. Subjects are fully informed and voluntarily consent to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy or to amlodipine
  2. Significant history of neurological, cardiovascular, digestive, respiratory, urinary, hematological, dysmetabolism or other diseases (such as psychosis) which is unfavorable to the study
  3. History of postural hypotension
  4. Blood donation or lost more than 400mL blood within 3 months prior to the study
  5. Use of medications within 2 weeks before the study
  6. Volunteer in any other clinical drug study within 3 months prior to this study
  7. Drug abuse or alcohol abuse (220ml beer /day or >5 times in 2 hours)
  8. Smoker (>10 cigarettes/day)
  9. A positive result in surface antigen (HBsAg), anti- virus (HCV) antibodies, a syphilis test, or an (HIV) test
  10. Abnormal chest X-ray results with clinical significance
  11. Women of , pregnant and lactating women.
  12. Other unfavorable factors diagnosed by investigators.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    LANDI-Amlodipine Besylate Tablet 5mg

    During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.

    Drug: LANDI-Amlodipine Besylate Tablet 5mg

  • Active comparator
    Norvasc Tablets 5mg

    During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.

    Drug: Norvasc Tablets 5mg

Interventions

  • LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.

    Also known as: Amlodipine Tablet 5mg

  • Norvasc Tablet 5mg will be used as a comparator drug for the BE study.

    Also known as: Amlodipine Tablet 5mg

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Peak Plasma Concentration (Cmax)

    Time frame: 144 hours

Secondary outcomes

  1. Bioequivalence based on Area under the plasma concentration versus time curves (AUC)

    Time frame: 144 hours

07

Study locations

1 site
  • Shanghai Haini Pharmaceutical Co., Ltd.
    Shanghai, 201318, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Mar 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 28, 2016
StartActual
Dec 23, 2016
Primary completionActual
Mar 21, 2017
CompletionActual
Mar 21, 2017
Last update
Oct 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02974439
Lead sponsor
Shanghai Haini Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 28, 2016
Start date
Dec 23, 2016
Primary completion
Mar 21, 2017
Completion
Mar 21, 2017
Last update
Oct 13, 2017

Study contacts

Yanmei Liu
principal investigator · Shanghai Xuhui Central Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion